SCHEMBL3192014

SCHEMBL3192014

O=C(NCCNC(=O)c1ccccc1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.77
POLB P06746 1/20 0.77
GAA P10253 1/20 0.74
SMN1; SMN2 Q16637 4/20 0.70
NPC1 O15118 5/20 0.68
RAB9A P51151 5/20 0.68
EPHX2 P34913 1/20 0.68
PRSS1 P07477 1/20 0.68
CTSG P08311 1/20 0.68
CTRB1 P17538 1/20 0.68
CMA1 P23946 1/20 0.68
KMT2A Q03164 1/20 0.67
HDAC3 O15379 4/20 0.66
HDAC1 Q13547 4/20 0.66
HDAC7 Q8WUI4 4/20 0.66
HDAC2 Q92769 4/20 0.66
HDAC8 Q9BY41 4/20 0.66
HDAC6 Q9UBN7 4/20 0.66
HDAC4 P56524 3/20 0.66
HDAC10 Q969S8 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321556 0.93 LMNA (0.75) LMNAPOLBGAASMN1; SMN2NPC1
SCHEMBL18689914 0.93 LMNA (0.69) LMNAPOLBGAASMN1; SMN2NPC1
SCHEMBL9491686 0.91 NPC1 (0.75) LMNAPOLBGAASMN1; SMN2NPC1
SCHEMBL8779817 0.91 HDAC1 (0.79) LMNAPOLBGAASMN1; SMN2NPC1
SCHEMBL1754794 0.89 LMNA (0.70) LMNAPOLBGAASMN1; SMN2NPC1
SCHEMBL10293576 0.89 LMNA (0.65) LMNAPOLBGAASMN1; SMN2NPC1
SCHEMBL16248437 0.89 LMNA (0.70) LMNAPOLBGAASMN1; SMN2NPC1
SCHEMBL9489804 0.89 HDAC1 (0.82) LMNAPOLBGAASMN1; SMN2NPC1
SCHEMBL20734829 0.89 HDAC1 (0.82) LMNAPOLBGAASMN1; SMN2NPC1
SCHEMBL604217 0.89 GAA (0.65) LMNAPOLBGAASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666971-B2 Amide/urea-modified liquid diphenylmethane diisocyanates BAYER MATERIALSCIENCE LLC (US) 2010-02-23 US claimed
US-20080139777-A1 Amide/urea-modified liquid diphenylmethane diisocyanates BAYER MATERIALSCIENCE LLC 2008-06-12 US claimed
WO-2008060454-A2 AMIDE/UREA-MODIFIED LIQUID DIPHENYLMETHANE DIISOCYANATES BAYER MATERIALSCIENCE LLC (US) 2008-05-22 WO claimed
EP-0447171-B1 Polysulfate of cyclodextrin derivative and process for preparing the same TANABE SEIYAKU CO (JP) 1994-11-02 EP claimed
US-5248675-A Viricides for HIV TANABE SEIYAKU CO., LTD. 1993-09-28 US claimed
EP-0447171-A2 Polysulfate of cyclodextrin derivative and process for preparing the same TANABE SEIYAKU CO., LTD. (JP) 1991-09-18 EP claimed
EP-0434734-A1 MOLDING COMPOSITIONS BASED ON POLY(1,4-CYCLOHEXYLENE DIMETHYLENE TEREPHTHALATE) CONTAINING AN AMIDE CRYSTALLIZATION AID EASTMAN KODAK COMPANY (US) 1991-07-03 EP claimed
WO-1990003413-A1 MOLDING COMPOSITIONS BASED ON POLY(1,4-CYCLOHEXYLENE DIMETHYLENE TEREPHTHALATE) CONTAINING AN AMIDE CRYSTALLIZATION AID EASTMAN KODAK COMPANY (US) 1990-04-05 WO claimed
US-4894404-A HEAT RESISTANCE MOLDINGS EASTMAN KODAK COMPANY (US) 1990-01-16 US claimed
US-20260124226-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-05-07 US disclosed
EP-4705284-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO Emory University (US) 2026-03-11 EP disclosed
CN-119118882-A Olatinib intermediate and preparation method thereof and preparation method of Olatinib 浙江荣耀生物科技股份有限公司 2024-12-13 CN disclosed
CN-119119055-A Preparation method of olantinib 浙江荣耀生物科技股份有限公司 2024-12-13 CN disclosed
WO-2024233354-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2024-11-14 WO disclosed
EP-0447171-A2 Polysulfate of cyclodextrin derivative and process for preparing the same TANABE SEIYAKU CO., LTD. (JP) 1991-09-18 EP disclosed
EP-0162663-B1 PROCESS FOR PRODUCING HEAT-RESISTANT MOLDINGS MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1991-08-28 EP disclosed
US-4894404-A HEAT RESISTANCE MOLDINGS EASTMAN KODAK COMPANY (US) 1990-01-16 US disclosed
US-4663375-A THERMOPLASTIC RESIN AND AROMATIC AMIDE MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1987-05-05 US disclosed
EP-0162663-A2 Process for producing heat-resistant moldings MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1985-11-27 EP disclosed
US-4386053-A IMPREGNATION OF SUBSTRATE WITH ORGANIC PEROXIDE, CHROMOGEN, BUFFER AND STABILIZER TERUMO CORPORATION (JP) 1983-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124226-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO NSUN2, SARS1, SNRPE LMNA 1728/4885POLB 1624/4885GAA 2929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.